The EMS1 and CCND1 genes at chromosome 11q13 are ampli®ed in about 15% of primary breast cancers but appear to confer dierent phenotypes in ER positive and ER negative tumours. Since there are no published data on EMS1 expression in large series of breast cancers we examined the relationship of EMS1 expression with EMS1 gene copy number and expression of mRNAs for cyclin D1 and ER. In a subset of 129 patients, where matched tumour RNA and DNA was available, EMS1 mRNA overexpression was associated predominantly with gene ampli®cation (P=0.0061), whereas cyclin D1 mRNA overexpression was not (P=0.3142). In a more extensive series of 351 breast cancers, there was no correlation between cyclin D1 and EMS1 expression in the EMS1 and cyclin D1 overexpressors (P=0.3503). Although an association between EMS1 mRNA expression and ER positivity was evident (P=0.0232), when the samples were divided into quartiles of EMS1 or cyclin D1 mRNA expression, the increase in the proportion of ER positive tumours in the ascending EMS1 mRNA quartiles was not statistically signi®cant (P=0.0951). In marked contrast there was a signi®cant stepwise increase in ER positivity in ascending quartiles of cyclin D1 mRNA (P=0.030). A potential explanation for this dierence was provided by the observation that in ER positive breast cancer cells oestradiol treatment resulted in increased cyclin D1 gene expression but was without eect on EMS1. The relationship between EMS1 expression and clinical outcome was examined in a subset of 234 patients with median follow-up of 74 months. High EMS1 expression was associated with age 450 years (P=0.0001), postmenopausal status (P=0.0008), lymph node negativity (P=0.019) and an apparent trend for worse prognosis in the ER negative subgroup. These data demonstrate that overexpression of EMS1 mRNA is largely due to EMS1 gene ampli®ca-tion, is independent of cyclin D1 and ER expression and, in contrast to cyclin D1, is not regulated by oestrogen. Independent overexpression of these genes may confer dierent phenotypes and disease outcomes in breast cancer as has been inferred from recent studies of EMS1 and CCND1 gene ampli®cation.
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Keywords: EMS1; cyclin D1; breast cancer; prognosis Ampli®cation of chromosome locus 11q13 is a common feature of several human cancers including squamous cell carcinomas of the oesophagus, lung and head and neck as well as breast and bladder cancer (Peters et al., 1995) . There are at least two candidate oncogenes within the locus: CCND1 which encodes the cell cycle regulatory protein, cyclin D1 and EMS1 which encodes a v-src substrate, cortactin (Wu et al., 1991) . Since overexpression of the gene product normally accompanies gene ampli®cation much of the published work examining the role of EMS1 or cyclin D1 in primary breast cancer has employed 11q13 ampli®cation as a measure of overexpression. The larger studies provide strong evidence that CCND1 ampli®cation is associated with hormone receptor positivity and predicts for earlier relapse in the good prognosis ER positive and axillary lymph node negative groups (Borg et al., 1991; Berns et al., 1995; Seshadri et al., 1996) .
EMS1 is located approximately 800 kb telomeric to the CCND1 gene at 11q13 and encodes an 80/85 kDa cytoskeletal actin-binding protein (Wu et al., 1991) . The redistribution of the overexpressed cytoplasmic EMS1 protein to podosomal structures at the cellsubstratum junctions in 11q13 ampli®ed squamous carcinoma cell lines (Schuuring et al., 1993) is accompanied by post-translational modi®cation of p80 EMS1 protein into its p85 form (van Damme et al., 1997) , suggesting that EMS1 may have a role in cellular adhesion and tumour spread. Several previous studies indicate that CCND1 and EMS1 are frequently co-ampli®ed (Schuuring et al., 1992a, b; Gaey et al., 1993) , whereas others have suggested that CCND1 and EMS1 may be in dierent amplicons at 11q13 (Karlseder et al., 1994) . A recently completed study from this laboratory demonstrated that EMS1 can be ampli®ed independently of CCND1, associating with dierent disease phenotypes in primary breast cancer . EMS1 ampli®cation was more frequently observed in ER positive tumours but, in marked contrast to studies with CCND1, the presence of EMS1 ampli®cation was associated with increased risk of early relapse in ER negative, and not ER positive, tumours .
In a small series of primary breast cancers, overexpression of both cyclin D1 and EMS1 mRNA was observed in all tumours with 11q13 ampli®cation, but overexpression of both genes was also noted in a small number of tumours without gene ampli®cation (Schuuring et al., 1992a) . In larger series of breast cancers, overexpression of both cyclin D1 mRNA and protein was signi®cantly more frequent than gene ampli®cation i.e. 45 ± 50% vs 13% respectively (Buckley et al., 1993; Fantl et al., 1993; Bartkova et al., 1994 Bartkova et al., , 1995 Gillett et al., 1994) , suggesting that CCND1 ampli®cation is not a good measure of cyclin D1 overexpression. Data from breast cancer cell lines indicate that in contrast, EMS1 overexpression generally results from gene ampli®cation (Campbell et al., 1996) . However, there are no published data on EMS1 gene expression in any large series of primary breast cancers. Thus, in this study we measured EMS1 mRNA levels in 351 breast cancer samples to assess the likely contribution of EMS1 gene ampli®cation to high levels of expression and to establish any relationships with cyclin D1 or ER gene expression and clinical outcome.
Expression of EMS1 mRNA was examined in 351 primary breast cancers. A single EMS1 transcript of 3.8 kb was clearly de®ned (Figure 1a ). Dierences in RNA loading were estimated by reprobing the ®lters with a cDNA for 36B4 (Laborda, 1991) . Each ®lter contained four control cell lines for normalization between the 22 ®lters. The ratio of EMS1: 36B4 mRNA signal intensity for each sample was normalized to that of MDA-MB-231, which was de®ned arbitrarily as 1.0 to yield`the relative expression of EMS1 mRNA'. Relative EMS1 mRNA levels ranged from 0 ± 12.5 with a median of 1.02, and the frequency distribution was positively skewed (Figure 1b ). Since the median was approximately 1, the cut-o point for overexpression of EMS1 was arbitrarily taken as 52. Of the 351 tumour samples, 65 (18.5%) exhibited EMS1 overexpression by this de®nition.
To investigate the hypothesis that EMS1 overexpression was due predominantly to gene amplification, DNA obtained from a subset of 129 samples was Southern blotted with up to three samples of peripheral blood lymphocyte (PBL) DNA as control on each ®lter. The ten Southern blots were sequentially probed with cDNAs for EMS1, cyclin D1 and, as a control for DNA loading, b-actin (Figure 2a ). The ratio of EMS1 or CCND1 signal: b-actin signal was used to determine relative gene copy number and samples with a 5twofold increase in gene copy number were considered ampli®ed. Of the 129 samples, 12 (9.3%) were ampli®ed for EMS1, 7 (5.4%) were ampli®ed for both EMS1 and CCND1, and 16 (12.4%) were ampli®ed for either EMS1 or CCND1. The frequency distribution for EMS1 mRNA in this subset of 129 tumours was very similar to that of the whole population of 351, with a median of 1.01. When the relative expression of EMS1 mRNA was plotted against the relative gene copy number for EMS1 detected in matched DNA from the same 129 tumours, there was a statistically signi®cant positive correlation between EMS1 gene copy number and mRNA levels (P=0.0298). The average expression of EMS1 mRNA among the EMS1 overexpressors was signi®cantly higher in EMS1 ampli®ed tumours than in the non-ampli®ed group (P=0.0061) (Figure 2b ), indicating that overexpression of EMS1 mRNA was more common with gene ampli®cation than without. Since cyclin D1 overexpression occurs more frequently than 11q13 ampli®cation (Buckley et al., 1993; Bartkova et al., 1994; Gillett et al., 1994) , the same analysis was performed for cyclin D1 mRNA and CCND1 gene ampli®cation. In contrast to EMS1, the relationship between cyclin D1 mRNA expression and CCND1 gene copy number was not statistically signi®cant (P=0.0513) and the average expression of cyclin D1 mRNA among the cyclin D1 overexpressors was not statistically dierent with or without CCND1 ampli®cation (P=0.3142) (Figure 2b ), con®rming that cyclin D1 mRNA overexpression can occur without CCND1 ampli®cation in a substantial proportion of tumours.
The data presented in Figure 2 together with our recent data demonstrating a lack of concordance in the degree of EMS1 and CCND1 ampli®cation , suggest that overexpression of these two genes is unlikely to be related. This was con®rmed by linear regression analysis of those samples overexpressing either EMS1 or cyclin D1 mRNA which showed no correlation between the relative overexpression of EMS1 and cyclin D1 mRNA levels (P=0.3503) (Figure 3 ).
Since previously published data have indicated that ampli®cation of either CCND1 or EMS1 is associated -134 (20, 10, 20 , 5 mg RNA, respectively) and 20 mg of RNA from each of 18 primary breast cancer samples is shown. The source of tumour samples and control cell lines and the method of Northern analysis were described previously (Buckley et al., 1993; Hui et al., 1996) . The ®lters were sequentially probed with a 32 P-dCTP-labelled EMS1 cDNA (Campbell et al., 1996) and 36B4 cDNA. The relative EMS1 mRNA level was calculated from the tumour EMS1 mRNA signal/tumour 36B4 mRNA signal divided by the EMS1 mRNA signal of MDA-MB-231/36B4 mRNA signal of MDA-MB-231. The size of the EMS1 transcript is indicated. (b) Frequency distribution of EMS1 mRNA levels in 351 primary breast cancers EMS1 gene expression in breast cancer R Hui et al with ER positivity (Adnane et al., 1989; Fantl et al., 1990; Borg et al., 1991; Berns et al., 1992; Seshadri et al., 1996; Hui et al., 1997) and cyclin D1 mRNA is positively correlated with ER mRNA levels , the relationship between EMS1 mRNA and ER expression was examined. In common with the EMS1 ampli®cation data, there was a positive correlation between EMS1 mRNA expression and ER positivity (P=0.0232). However, when ER positivity in dierent quartiles of EMS1 mRNA was calculated and analysed using simple regression, in contrast to the signi®cant stepwise increase in the proportion of ER positive tumours in ascending cyclin D1 mRNA quartiles (P=0.0301), no such relationship was observed in the percentage of ER positive tumours with increasing EMS1 mRNA quartiles (P=0.0951) (Figure 4) . Moreover, logistic regression analysis showed that the magnitude of increase in the proportion of ER positive tumours in the ascending cyclin D1 quartiles was signi®cantly dierent from that in the EMS1 quartiles (P=0.0092). Using simple regression analysis, there was a signi®cant positive correlation between EMS1 mRNA and ER mRNA levels in the total population of 351 samples (P=0.0001). However, when the large cluster of samples around the mode was excluded, there was no relationship between EMS1 mRNA and ER mRNA in the ER positive, EMS1 mRNA overexpressors (P=0.9358). On the other hand, the same analysis performed on the group of ER positive tumours with cyclin D1 overexpression showed a statistically signi®cant positive correlation between cyclin D1 and ER mRNA (P=0.0103). It is concluded that even though both EMS1 and cyclin D1 expression are associated with ER status, there are signi®cant quantitative dierences in their relationship with ER mRNA levels. Given the known positive correlation between 11q13 ampli®cation and ER positivity (Fantl et al., 1993; Seshadri et al., 1996; Hui et al., 1997) , and the stronger relationship between EMS1 ampli®cation and overexpression than between CCND1 ampli®cation and Figure 2 (a) Ampli®cation of CCND1 and EMS1 genes in primary breast cancers. DNA (10 mg) from a random subset of 129 breast tumour samples was digested with EcoRI (Promega) at 378C and Southern blotted as previously described (Buckley et al., 1993) . A representative Southern blot containing 10 mg of DNA from each of 15 primary breast tumours and three DNA samples from normal human peripheral blood lymphocytes as controls were sequentially probed with a 32 P-dCTP-labelled EMS1 cDNA, cyclin D1 cDNA, and b-actin cDNA. The relative EMS1 gene copy number=tumour DNA EMS1 signal/tumour DNA b-actin signal divided by the mean of three control DNA EMS1 signal/ control DNA b-actin signal. (b) Relationship between gene ampli®cation and mRNA overexpression of EMS1 or cyclin D1 in 129 primary breast cancers. The mean relative mRNA overexpression of EMS1 or cyclin D1+standard errors in the ampli®ed i.e. 5twofold increase in gene copy number (shaded bars) and non-ampli®ed i.e. 5twofold increase in gene copy number (open bars) tumours are shown. The relationship between gene ampli®cation and gene overexpression of both EMS1 and cyclin D1 was analysed using Mann ± Whitney U test (EMS1, P=0.0061; cyclin D1, P=0.3142) (Figure 2b ) one might have expected a closer relationship between EMS1 mRNA and ER mRNA than between cyclin D1 and ER expression. A potential explanation lies in the recent observations that cyclin D1 gene expression can be induced by oestrogen in breast cancer cells (Altucci et al., 1996; Foster and Wimalasena, 1996; Prall et al., 1997) . Thus oestrogen regulation of cyclin D1 and EMS1 gene expression was tested in the present study. In contrast to the marked induction of cyclin D1 mRNA, there was no change in the level of EMS1 mRNA following oestrogen treatment ( Figure 5 ). Clinical data were available on 234 patients with a median follow-up of 74 months (range 25 ± 107 months). At the time of analysis, 86 patients had relapsed, 58 had developed distant metastases and 48 had died of breast cancer. For analyses of the relationship between EMS1 mRNA and other clinicopathological parameters or survival outcome, patients were divided into two equal groups according to their EMS1 mRNA levels using the median as cut-o. High EMS1 mRNA expression was more prevalent in the older age group i.e. 450 years (P=0.0001) and in postmenopausal women (P=0.0008), and was associated with axillary lymph node negativity (P=0.019) and ER positivity (P=0.004) ( Table 1 ). There was no association between EMS1 mRNA levels and diseasefree or overall survival in the whole population. However, in the ER negative subgroup (n=59), there was an apparent divergence of the cumulative proportion survival curves with a trend for worse prognosis in patients with high EMS1 expression ( Figure 6 ). A similar trend was also noted in patients with axillary lymph node negative disease (n=36) (data not shown). Figure 5 Eect of oestradiol treatment on the expression of EMS1 and cyclin D1 mRNA in MCF-7 human breast cancer cells. Cells were pretreated with 10 nM ICI 182780 for 48 h, then treated with 100 nM estradiol or vehicle and cells harvested at the times indicated (Prall et al., 1997) . Total RNA was harvested, Northern blotted and probed with EMS1, cyclin D1 and 36B4 cDNA as previously described (Buckley et al., 1993; Campbell et al., 1996) Both CCND1 and EMS1 are frequently ampli®ed in several human cancers but in contrast to the rapidly accumulating data on cyclin D1 overexpression in various tumour types, there are few data on EMS1 expression. Overexpression of EMS1 was observed in breast and squamous cancer cell lines (Schuuring et al., 1992a (Schuuring et al., 1993 Campbell et al., 1996; Patel et al., 1996) , and in a small series of primary breast cancers (Schuuring et al., 1992a) . The only published study to investigate the phenotypes conferred by overexpression of EMS1 in human tumours reported that 25 of 42 (59%) bladder tumours overexpressed EMS1 and higher expression was associated with less aggressive super®cial bladder cancers (Bringuier et al., 1996) . The current study is the ®rst of its type in breast cancer and clearly demonstrated high expression of EMS1 mRNA in at least 18% of primary cancers. Furthermore, the relationship of EMS1 overexpression to gene amplification, cyclin D1 and ER gene expression, clinicopathological parameters and disease outcome were investigated.
In a small series of breast cancers, overexpression of both cyclin D1 and EMS1 mRNA was observed in all tumours with 11q13 ampli®cation and in a minority of samples without 11q13 ampli®cation (Schuuring et al., 1992a) . Gillett et al. (1994) , however, reported that a larger proportion (19%, eight of 43) of breast cancers overexpressed cyclin D1 protein without 11q13 ampli®cation. In bladder cancer, again all tumours with ampli®cation had a clear overexpression of EMS1, but a substantial proportion of tumours (17 of 34) overexpressed EMS1 without gene ampli®cation (Bringuier et al., 1996) . Consistent with the previous reports suggesting that the frequency of cyclin D1 mRNA or protein expression is much higher than the frequency of 11q13 ampli®cation in breast cancers (Buckley et al., 1993; Bartkova et al., 1994 Bartkova et al., , 1995 Gillett et al., 1994) , the current study employing a panel of 129 breast tumours demonstrated that a statistically signi®cant proportion of tumours with increased expression of cyclin D1 can occur through ampli®cation-independent mechanisms. Although EMS1 mRNA overexpression occurred in some tumours without EMS1 ampli®cation, statistical analysis indicated that, unlike cyclin D1, EMS1 mRNA overexpression is largely due to EMS1 gene ampli®cation. Thus, EMS1 ampli®cation appears to be a better surrogate for EMS1 expression than CCND1 ampli®cation is for cyclin D1 expression. This is further supported by the fact that EMS1 amplification and overexpression are associated with similar phenotypes in breast cancer. In common with previous EMS1 ampli®cation data in an independent series of patients , high EMS1 mRNA expression in the present study was associated with age 450 years, ER positivity and an apparent worse prognosis in patients with ER negative or lymph node negative disease. Overexpression of epidermal growth factor receptor and c-erbB-2 are frequently observed in ER negative breast tumours. Since EMS1 is a potential downstream target of these receptors, increased expression with increased activation of EMS1 may facilitate tumour spread contributing to worse prognosis in this patient subgroup (discussed in Hui et al., 1997) . However, this association will need to be further investigated in a larger series of patients.
The relationship between cyclin D1 and EMS1 expression has not been studied in detail previously. In breast cancer cell lines, three of 20 (MDA-MB-134, -175, and -453) exhibited cooverexpression of EMS1 (Buckley et al., 1993; Campbell et al., 1996) . Of 25 bladder tumours overexpressing either EMS1 or cyclin D1 mRNA, seven exhibited more pronounced overexpression of one gene than the other (Bringuier et al., 1996) . Similarly, the current study of 351 primary breast cancers provides strong evidence that overexpression of EMS1 and cyclin D1 mRNA is independent. This is consistent with the ®nding that EMS1 gene amplification can occur independently of CCND1 gene ampli®cation and that gene ampli®cation is a major mechanism of overexpression of EMS1 but is a less important contributor to cyclin D1 overexpression. Furthermore, the regulation of cyclin D1 gene expression is under hormonal control while that of EMS1 is not Prall et al., 1997; Campbell, unpublished data) . Several recent studies have implicated oestrogen in the transcriptional activation of cyclin D1 gene expression (Altucci et al., 1996; Foster and Wimalasena, 1996; Prall et al., 1997) . However, regulation of EMS1 gene expression has not been studied in any detail. Given the reported association between 11q13 ampli®cation and ER positivity (Adnane et al., 1989; Fantl et al., 1990; Borg et al., 1991; Berns et al., 1992; Seshadri et al., 1996; Hui et al., 1997) and our demonstration that ampli®cation was the primary means of EMS1 overexpression, a positive association between EMS1 and ER mRNA levels might have been expected. However, in marked contrast to the positive correlation between cyclin D1 and ER expression there was no relationship between EMS1 and ER mRNA levels among the EMS1 overexpressors. Major contributing factors to the relationship between cyclin D1 and ER are likely to include the demonstrated regulation of cyclin D1 expression by oestrogen in breast cancer cells and recent evidence that cyclin D1 and ER gene expression are coordinately upregulated during dierentiation of breast epithelial cells (Neuman et al., 1997) .
In conclusion, although CCND1 and EMS1 are the only two known candidate oncogenes driving the frequently ampli®ed 11q13 locus in breast cancer, the products of these genes can be overexpressed independently and consequently a diversity of phenotypes may accompany dierent patterns of gene expression. Since EMS1 ampli®cation appears to be a good measure for EMS1 expression, the role of EMS1 overexpression in primary breast cancer may be deduced from the EMS1 ampli®cation data which predict early relapse in patients with lymph node negative or ER negative disease . The present study however, highlights the need to further evaluate the relationship between cyclin D1 expression and prognosis given that ampli®cation is a poor surrogate for overexpression. The ®ve studies reported to date have failed to reach a consensus: two reported an improved relapse-free and overall survival in the patients with cyclin D1 overexpressing tumours (Gillett et al., 1996; Pelosio et al., 1996) , whereas the other studies failed to identify any impact of cyclin D1 expression on survival (McIntosh et al., 1995; Michalides et al., 1996; van Diest et al., 1997) . Further studies are therefore required to elucidate the prognostic signi®cance of cyclin D1 and EMS1 overexpression.
